LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Inicio・Lista de Acciones・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Cerrado

SectorSalud

25.93 2.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

25.26

Máximo

26.48

Métricas clave
By Trading Economics
Ingresos	-2.8M -57M
Ventas	35K 730K
BPA	-1.01
Margen de beneficio	-7,753.425
Empleados	186
EBITDA	-1.1M -63M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+105.68% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	58M 1.5B
Apertura anterior	23.8
Cierre anterior	25.93

Noticias sobre sentimiento de mercado

By Acuity

50%

185 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

18.91 / 20.63 Soporte y Resistencia

Celldex Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 nov 2025, 18:59 UTC

Principales Movimientos del Mercado

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Charlas de Mercado

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Charlas de Mercado

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Charlas de Mercado

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Ganancias

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Ganancias

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Ganancias

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Ganancias

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Ganancias

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Ganancias

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Ganancias

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Charlas de Mercado

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Charlas de Mercado

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Charlas de Mercado

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Adquisiciones, fusiones, absorciones

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Ganancias

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Ganancias

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Adquisiciones, fusiones, absorciones

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Adquisiciones, fusiones, absorciones

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Charlas de Mercado

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparación entre iguales

Cambio de precio

Celldex Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

105.68% repunte

Estimación a 12 meses

Media 52.55 USD 105.68%

Máximo 90 USD

Mínimo 21 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

18.91 / 20.63Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

185 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.